ACHONDROPLASIA
Clinical trials for ACHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new ACHONDROPLASIA trials appear
Sign up with your email to follow new studies for ACHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could this pill help kids with dwarfism grow faster?
Disease control CompletedThis study tested a drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The drug aims to manage the condition by improving height, but…
Matched conditions: ACHONDROPLASIA
Phase: PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 26, 2026 11:23 UTC
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested an oral drug called infigratinib in 84 children aged 3 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if the drug could safely increase growth rate by targeting a specific protein involved in bone development. Children who had a…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Weekly shot shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested a weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia (a common form of dwarfism). The goal was to see if it safely improves growth rate compared to a placebo over one year. After the blinded phase, all children could receive the…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
No treatment, just tracking: PROPEL study follows kids with achondroplasia
Knowledge-focused CompletedThis study followed 271 children with achondroplasia, aged 2.5 to 17, to track their growth, medical issues, and quality of life over time. No medication or treatment was given. The goal was to better understand the condition and its effects on daily life.
Matched conditions: ACHONDROPLASIA
Sponsor: QED Therapeutics, a BridgeBio company • Aim: Knowledge-focused
Last updated May 26, 2026 11:18 UTC